Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan
1 other identifier
observational
300
1 country
1
Brief Summary
This proposal responds to Request for Applications RFA-MH-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the NIMH Human Genetics Initiative and to apply genomic methods to further our understanding of the molecular etiology of the disorder. The overarching aims of this proposal are to quickly and cost-effectively ascertain a large sample of trio families affected by schizophrenia, and to discover causal variants for the disorder in the first family-based genome-wide association study (GWAS) of the disorder. In Taiwan, there is no such kind of policy to support this kind of GWAS study as it is a very expensive study, including collecting large family samples and genome-wide SNP scanning. The investigators, thus, collaborate with Professor Ming T, Tsuang and his intended subcontracted researchers to apply for this project. The investigators, the research team in Taiwan, will collect 3800 trio families (11400 subjects) of schizophrenia. The investigators will meet the overarching goals of this project by accomplishing several Specific Aims, as follows: 1) Rapidly ascertain schizophrenia trio families from Taiwanese clinical ascertainment sites; 2) Supplement NIMH Genetics Initiative collections by sending all clinical data and biomaterials to the appropriate repositories; 3) Assess the association of schizophrenia with a genome-wide panel of single-nucleotide polymorphisms (SNPs) and their constituent haplotypes; 4) Analyze quantitative schizophrenia phenotypes such as age at onset ; 5) Perform a genome-wide survey for copy-number variations related to schizophrenia; 6) Test for gene-gene interactions (epistasis); and 7) Test for gene-environment interactions, such as the well-established effect of season of birth.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
December 29, 2010
CompletedFirst Posted
Study publicly available on registry
May 20, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedMay 20, 2011
May 1, 2011
3.2 years
December 29, 2010
May 19, 2011
Conditions
Study Arms (1)
Schizophrenia Family
Interventions
No intervention would be provided in this research, but need to draw blood
Eligibility Criteria
Schizophrenia patients and their biological parents
You may qualify if:
- clinical diagnosis of schizophrenia and their parents,and parents are still alive
You may not qualify if:
- person with Mental Retardation
- persons with epilepsy
- alcohol or substance abuse combined
- in combination with other organic brain damage syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Far Eastern Memorial Hospitallead
- National Taiwan University Hospitalcollaborator
Study Sites (1)
Far Eastern Memorial Hospital
Taipei, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Chi Shin Wu
Far Eastern Memorial Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 29, 2010
First Posted
May 20, 2011
Study Start
October 1, 2010
Primary Completion
December 1, 2013
Last Updated
May 20, 2011
Record last verified: 2011-05